Conclusions: One year of pemafibrate therapy improves markers of hepatic inflammation, function, and fibrosis in NAFLD patients in whom long-term SGLT2 inhibitor therapy failed to normalize serum ALT. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.